Does BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases (BCRX) Pay a Dividend? (2026)
Short answer
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases (BCRX) pays little or no dividend; like many growth-oriented companies it reinvests cash rather than paying income. A dividend is a slice of profits returned to shareholders, and the yield is that payout divided by the share price, so it drifts as both change. Figures here are approximate; verify the current number with your broker.
Does BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases (BCRX) pay a dividend?
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases (BCRX) currently returns little or nothing as a dividend. BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on GAAP earnings, since 2026 results were dominated by a roughly $698 million one-time non-cash acquired-IPR&D charge from the Astria deal that produced a large GAAP operating loss. On a non-GAAP basis the company reported operating profit and reaffirmed full-year revenue guidance. Because so much value sits in a single growing product plus a late-stage pipeline candidate, the market cap reflects expectations for peak ORLADEYO sales and navenibart success as much as trailing figures.
How to think about BCRX's dividend
- Yield is a snapshot: minimal today, but it moves with price and payout.
- Total return vs income: dividends are one part of return; price change is usually the bigger part for a name like BCRX.
- Reinvest or take income: a DRIP compounds; taking the cash gives income now.
- For more yield: dedicated dividend stocks and ETFs target higher payouts. See the best dividend ETFs.
The bottom line on the BCRX dividend
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases (BCRX) is not an income stock; if you own it, it is for growth or total return, not the dividend. For the full picture see the BCRX guide. Walnut can show how BCRX fits your real portfolio. It is not an investment adviser.
Build a basket around BCRX with Walnut
Use BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Does BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases (BCRX) pay a dividend?
+
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases (BCRX) pays little or no dividend; like many growth-stage companies it tends to reinvest cash rather than return it as income. Verify the current policy on BCRX's investor relations page.
What is BCRX's dividend yield?
+
BCRX's yield is minimal or zero. Companies prioritizing growth often pay no dividend and return cash through buybacks instead, if at all.
How often does BCRX pay its dividend?
+
US companies that pay dividends, like BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases if it does, typically distribute them quarterly. Confirm the exact schedule and ex-dividend dates on BCRX's investor relations page before relying on the timing.
Can I reinvest BCRX dividends?
+
Yes. Most brokers offer automatic dividend reinvestment (a DRIP) so any BCRX dividend buys more shares automatically. It compounds over time but is still taxable in a taxable account.
Is BCRX a good dividend stock?
+
Walnut is informational, not investment advice. BCRX is a growth or total-return name rather than an income stock. Dedicated dividend stocks and ETFs target higher, steadier yield; match the choice to whether you want income now or growth.
Walnut is informational, not investment advice. Dividend figures are approximate and dated; verify current yield, schedule, and policy with BCRX's investor relations page or your broker.